Remark: Barbiturates may increase adverse effects, including respiratory despair, made by poisonous doses of TCAs. With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the extent or result of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.
pentobarbital will reduce the level or impact of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the level or impact of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unfamiliar.
pentobarbital will reduce the level or effect of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.
pentobarbital will lower the extent or impact of darunavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Steer clear of; coadministration with CYP3A inducers may well bring about lowered plasma concentrations of elvitegravir and/or maybe a concomitantly administered protease inhibitor and lead to lack of therapeutic outcome also to feasible resistance
pentobarbital will decrease the level or effect of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Watch INR a lot more often if coadministered with inducers of such isoenzymes and modify warfarin dose if wanted.
Remark: Barbiturates may possibly enhance adverse effects, which include respiratory melancholy, produced by poisonous doses of TCAs. With therapeutic doses of TCAs, barbiturates enhance metabolism and decrease blood concentrations of TCAs.
fentanyl transdermal and pentobarbital each maximize sedation. Stay away from or Use Alternate Drug. Restrict use to clients for whom alternate therapy alternatives are inadequate
pentobarbital will minimize the level or outcome of atorvastatin website by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lessen the extent or effect of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Keep away from coadministration of lefamulin with solid or moderate CYP3A inducers unless the advantage outweighs threats. Monitor for reduced efficacy.
pentobarbital will lessen the extent or influence of ramelteon by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.